Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes

A randomized phase 3 trial of 731 Chinese adults with type 2 diabetes compared once-weekly mazdutide (4 mg and 6 mg) versus dulaglutide 1.5 mg over 28 weeks. Mazdutide demonstrated superior glycaemic control (LS mean HbA1c differences vs dulaglutide: −0.24%, p=0.0032 for 4 mg; −0.30%, p=0.0003 for 6 mg) and greater weight loss (LS mean differences: −3.78% for 4 mg and −5.76% for 6 mg; both p<0.0001), with significantly more patients achieving HbA1c <7% plus ≥5% weight reduction (p<0.0001). Safety was generally acceptable but with a higher incidence of gastrointestinal adverse events (diarrhoea, nausea, vomiting) versus dulaglutide, which will be material for commercial and regulatory assessment.

Analysis

Market structure: Mazdutide’s 28-week superiority (HbA1c −0.24 to −0.30% and weight −3.78% to −5.76% vs dulaglutide) signals a credible challenger to dulaglutide (Eli Lilly’s Trulicity) in China and the dual-agonist segment globally. Direct winners are the mazdutide developer and CDMOs/biotech partners that can scale peptide production; direct losers are dulaglutide sales in China and incumbent pricing power for GLP-1 mono-therapies if payers demand discounts. If approved and reimbursed, expect a 5–15% share reallocation in the Chinese injectable T2D market within 12–24 months and downward pressure on price realizations by mid-2026.

Risk assessment: Key tail risks are (1) regulatory rejection or delayed NRDL listing in China (0–18 months), (2) emergent safety signals — higher GI AEs could increase discontinuation >10% and slow uptake, and (3) manufacturing scale constraints or COGS surprises that widen margins by −200–500 bps. Short-term market moves (days–weeks) will be sentiment-driven; material commercial impact is medium-term (6–24 months). Hidden dependency: Chinese NRDL/reimbursement decisions and licensing/partner deals will determine realized volume and royalty flows.

Trade implications: Direct actionable plays: modest short exposure to LLY (Eli Lilly) to express China dulaglutide downside and long exposure to peptide CDMOs (CTLT, TMO) or public Chinese biotech builders with dual-agonist pipelines. Use defined-risk option structures — 3–6 month put spreads on LLY sized 1–2% portfolio, and 6–12 month call spreads on CDMOs sized 1–3%. Pair trade: long mazdutide-developer/China-biotech ETF (if public) vs short LLY. Enter within 2–6 weeks; tighten stops if NRDL not filed within 12 months.

Contrarian angles: The market may overestimate immediate damage to global leaders (NVO, LLY); historical GLP-1 adoption (semaglutide/tirzepatide) shows multi-year diffusion and price resiliency. Worst-case for incumbents is not elimination but lower ASPs that expand patient pool, ultimately growing class volumes; therefore keep position sizes small (1–3%) and watch NRDL, phase-3 global readouts, and discontinuation rates >10% as binary triggers.

Key Decisions for Investors

• Establish a 1–2% portfolio short on Eli Lilly (LLY) via a 3–6 month put spread (e.g., buy 5–10% OTM put, sell 15% OTM put) to express downside risk from dulaglutide share loss in China; close if LLY announces a major China licensing deal or if shares gap down >15%.
• Allocate 1–3% long to peptide CDMOs (example tickers: CTLT, TMO) via 6–12 month call spreads to capture higher manufacturing demand if mazdutide scales; target 15–30% upside and take profits if CDS spreads widen or guidance misses by >10%.
• If a public issuer of mazdutide or a Chinese dual-agonist biotech is available, enter a 1–2% long position after confirming phase‑3 to NDA filing or partnership; exit if NRDL submission not made within 12 months or if discontinuation rates exceed 10%.
• Monitor three binary catalysts over 30–540 days: (1) NRDL/reimbursement decision (0–18 months), (2) global phase‑3/Regulatory filings (3–24 months), and (3) discontinuation/adverse-event signals >10%; adjust positions within 48 hours of each catalyst outcome.